4AB Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$149.62 |
| 52 Week High | US$168.92 |
| 52 Week Low | US$118.80 |
| Beta | 0.59 |
| 1 Month Change | -1.76% |
| 3 Month Change | -7.01% |
| 1 Year Change | 10.58% |
| 3 Year Change | 54.97% |
| 5 Year Change | n/a |
| Change since IPO | 234.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4AB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -2.2% | 2.5% |
| 1Y | 10.6% | -25.2% | 6.0% |
Return vs Industry: 4AB exceeded the German Biotechs industry which returned -25.2% over the past year.
Return vs Market: 4AB exceeded the German Market which returned 6% over the past year.
Price Volatility
| 4AB volatility | |
|---|---|
| 4AB Average Weekly Movement | 2.5% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4AB has not had significant price volatility in the past 3 months.
Volatility Over Time: 4AB's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| 4AB fundamental statistics | |
|---|---|
| Market cap | €263.48b |
| Earnings (TTM) | €5.52b |
| Revenue (TTM) | €50.50b |
47.7x
P/E Ratio5.2x
P/S RatioIs 4AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4AB income statement (TTM) | |
|---|---|
| Revenue | US$54.40b |
| Cost of Revenue | US$16.77b |
| Gross Profit | US$37.63b |
| Other Expenses | US$31.68b |
| Earnings | US$5.95b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.37 |
| Gross Margin | 69.17% |
| Net Profit Margin | 10.94% |
| Debt/Equity Ratio | 924.1% |
How did 4AB perform over the long term?
See historical performance and comparison